Ceptaris Gains FDA Nod; Inks $250M M&A Deal with Actelion
By Nuala Moran
Wednesday, August 28, 2013
LONDON – Barring the dotting of a few i’s and crossing of a few t’s, the $250 million acquisition of Ceptaris Therapeutics Inc. by the Swiss biotech Actelion Ltd. is ready to go ahead, after Ceptaris announced FDA approval of its only product, Valchlor.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.